Compare · BDX vs DRIO
BDX vs DRIO
Side-by-side comparison of Becton Dickinson and Company (BDX) and DarioHealth Corp. (DRIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and DRIO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $41.33B, about 751.6x DRIO ($55.0M).
- Over the past year, BDX is down 13.0% and DRIO is down 47.9% - BDX leads by 35.0 points.
- BDX has been more active in the news (10 items in the past 4 weeks vs 2 for DRIO).
- BDX has more recent analyst coverage (25 ratings vs 4 for DRIO).
- Company
- Becton Dickinson and Company
- DarioHealth Corp.
- Price
- $150.14-0.71%
- $7.50+5.04%
- Market cap
- $41.33B
- $55.0M
- 1M return
- -2.01%
- +0.60%
- 1Y return
- -12.95%
- -47.92%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 2
- Recent ratings
- 25
- 4
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
DarioHealth Corp.
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is based in New York, New York.
Latest BDX
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
- EVP and President, BDI Menziuso Peter was granted 14,258 shares (SEC Form 4)
- New insider Menziuso Peter claimed no ownership of stock in the company (SEC Form 3)
- Becton Dickinson and Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Revenue Officer Feld Michael sold $11,051 worth of shares (75 units at $147.35) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,084 units (SEC Form 4)
- SEC Form SD filed by Becton Dickinson and Company
- SEC Form CERT filed by Becton Dickinson and Company
- BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
- Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Peter Menziuso Named EVP and President, BD Interventional
Latest DRIO
- Dario Presents Four Studies at American Diabetes Association Scientific Sessions Highlighting Commercial and Clinical Value of its Digital Health Platform
- Dario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible Lives
- DarioHealth Reports First Quarter 2026 Financial and Operating Results
- SEC Form 10-Q filed by DarioHealth Corp.
- SEC Form SD filed by DarioHealth Corp.
- DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026
- Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research
- SEC Form 3 filed by new insider Palumbo John R
- DarioHealth Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling